CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

An advocacy group that includes the main pharmaceutical lobbying organization, PhRMA, as a member is complaining that a commercial Hims & Hers Health (NYSE:HIMS) is slated to run during the Super Bowl ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...